ECSP066397A - Forma farmacéutica sólida de posología - Google Patents

Forma farmacéutica sólida de posología

Info

Publication number
ECSP066397A
ECSP066397A EC2006006397A ECSP066397A ECSP066397A EC SP066397 A ECSP066397 A EC SP066397A EC 2006006397 A EC2006006397 A EC 2006006397A EC SP066397 A ECSP066397 A EC SP066397A EC SP066397 A ECSP066397 A EC SP066397A
Authority
EC
Ecuador
Prior art keywords
solid pharmaceutical
posology
pharmaceutical form
pharmaceutically acceptable
dosage form
Prior art date
Application number
EC2006006397A
Other languages
English (en)
Inventor
Joerg Rosenberg
Ulrich Reinhold
Bernd Liepold
Gunther Derndl
Jorg Breitenbach
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ECSP066397A publication Critical patent/ECSP066397A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una forma farmacéutica sólida de posología que provee una mejorada biodisponibilidad oral, es presentada para los inhibidores de HIV proteasa. En particular, la forma de posología consiste en una dispersión sólida de al menos un inhibidor de proteasa HIV y al menos un polímero soluble en agua farmacéuticamente aceptable, y al menos un surfactante farmacéuticamente aceptable, el mencionado polímero soluble en agua con un Tg de al menos alrededor de 50º C., preferiblemente, el surfactante farmacéuticamente aceptable con un valor de HLB de alrededor de 4 a 10.
EC2006006397A 2003-08-28 2006-02-24 Forma farmacéutica sólida de posología ECSP066397A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form
EP2004027401 2004-08-23

Publications (1)

Publication Number Publication Date
ECSP066397A true ECSP066397A (es) 2006-08-30

Family

ID=34217089

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006397A ECSP066397A (es) 2003-08-28 2006-02-24 Forma farmacéutica sólida de posología

Country Status (31)

Country Link
US (1) US20050048112A1 (es)
EP (6) EP2258346B1 (es)
JP (6) JP4815348B2 (es)
KR (5) KR101132602B1 (es)
CN (5) CN105106104A (es)
AT (1) ATE516017T1 (es)
AU (3) AU2004283087C1 (es)
CA (2) CA2689639C (es)
CR (3) CR8256A (es)
CY (5) CY1111981T1 (es)
DK (5) DK2942051T3 (es)
EA (4) EA033224B1 (es)
EC (1) ECSP066397A (es)
ES (5) ES2653762T3 (es)
HK (1) HK1257502A1 (es)
HR (1) HRP20110555T1 (es)
HU (3) HUE038792T2 (es)
IL (3) IL173939A (es)
ME (2) ME00130B (es)
MX (2) MXPA06002346A (es)
NO (3) NO330282B1 (es)
NZ (2) NZ579622A (es)
PL (5) PL2942051T3 (es)
PT (5) PT2258345T (es)
RS (2) RS59969B1 (es)
SG (3) SG145690A1 (es)
SI (5) SI2258344T1 (es)
TW (1) TWI342221B (es)
UA (1) UA85564C2 (es)
WO (1) WO2005039551A2 (es)
ZA (3) ZA200801362B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
US20080317852A1 (en) * 2005-12-14 2008-12-25 Amar Lulla Pharmaceutical Combination
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
WO2008017867A2 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition with at least one water insoluble polymer
CA2669938C (en) * 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
EP4403221A3 (en) 2007-02-23 2024-10-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
CN101959506A (zh) * 2008-02-28 2011-01-26 雅培制药有限公司 片剂和其制备方法
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
BR122021018683B1 (pt) * 2008-10-07 2022-11-16 Kudos Pharmaceuticals Limited Formulação farmacêutica de 4-[3-(4-ciclopropanocarbonil- piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona, uso de um polímero de matriz, forma de dosagem e método para produzir uma dispersão amorfa sólida
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
US20110034489A1 (en) 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012120541A2 (en) * 2011-03-07 2012-09-13 Hetero Research Foundation Amorphous form of lopinavir and ritonavir mixture
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
WO2013025449A1 (en) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
HUE027829T2 (en) 2012-03-07 2016-11-28 Ratiopharm Gmbh Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
ES2587559T3 (es) 2012-03-07 2016-10-25 Ratiopharm Gmbh Forma farmacéutica que comprende lopinavir y ritonavir
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
WO2014048783A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
CN104661652B (zh) 2012-09-27 2018-08-28 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
RU2505286C1 (ru) 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
EP3758683A1 (en) * 2018-03-02 2021-01-06 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
WO2000074677A2 (en) 1999-06-04 2000-12-14 Abbott Laboratories Improved pharmaceutical formulations
DE60017444T2 (de) 1999-11-12 2006-02-09 Abbott Laboratories, Abbott Park Pharmazeutische formulierungen auf basis fester dispersionen
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
JP2005500313A (ja) 2001-06-22 2005-01-06 ファイザー・プロダクツ・インク 基材中の低可溶性薬物の固体分散体および溶解度向上性ポリマーを含有する医薬品組成物
WO2003063833A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
DE10213242A1 (de) * 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2669938C (en) 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations

Also Published As

Publication number Publication date
HUE038792T2 (hu) 2018-11-28
JP5903413B2 (ja) 2016-04-13
DK1663183T3 (da) 2011-08-29
ES2367173T3 (es) 2011-10-31
SI2942051T1 (en) 2018-06-29
JP2011126898A (ja) 2011-06-30
CY1111981T1 (el) 2015-11-04
CN101919858B (zh) 2013-10-30
ME00130B (me) 2010-10-10
EA201301045A1 (ru) 2014-05-30
DK2258345T3 (en) 2017-01-16
CA2689639A1 (en) 2005-05-06
PL2258345T3 (pl) 2017-03-31
AU2010238573A1 (en) 2010-11-18
HK1217298A1 (en) 2017-01-06
HK1145969A1 (en) 2011-05-13
EA033224B1 (ru) 2019-09-30
EA200900292A1 (ru) 2009-06-30
EA020992B1 (ru) 2015-03-31
IL173939A (en) 2017-03-30
HK1094766A1 (en) 2007-04-13
AU2004283087B2 (en) 2007-09-20
CA2536638C (en) 2010-04-06
HUE031153T2 (en) 2017-07-28
KR101457967B1 (ko) 2014-11-07
SG10201507902UA (en) 2015-10-29
CN1901884A (zh) 2007-01-24
CR20120661A (es) 2013-03-13
KR101132602B1 (ko) 2012-04-06
AU2007249115B2 (en) 2010-08-12
NO20100367L (no) 2006-05-29
NZ579622A (en) 2011-01-28
PL2258346T3 (pl) 2018-01-31
PT1663183E (pt) 2011-08-25
PT2258345T (pt) 2017-01-20
TWI342221B (en) 2011-05-21
CY1119651T1 (el) 2018-04-04
KR20060121837A (ko) 2006-11-29
IL207260A (en) 2017-10-31
EP2258345A3 (en) 2011-01-19
EP1663183A2 (en) 2006-06-07
EP2258346B1 (en) 2017-09-27
EP2942051B1 (en) 2018-01-17
ES2399810T3 (es) 2013-04-03
RS20181262A1 (sr) 2019-02-28
CN102772380A (zh) 2012-11-14
JP5498411B2 (ja) 2014-05-21
ES2653762T3 (es) 2018-02-08
US20050048112A1 (en) 2005-03-03
CA2689639C (en) 2014-06-10
CN102764244A (zh) 2012-11-07
CR8256A (es) 2008-01-11
NO335326B1 (no) 2014-11-10
WO2005039551A2 (en) 2005-05-06
EP2258344A3 (en) 2011-01-19
DK2942051T3 (en) 2018-05-07
EP3354261A1 (en) 2018-08-01
SG145690A1 (en) 2008-09-29
CN102772380B (zh) 2015-08-19
AU2007249115A1 (en) 2008-01-10
SI2258345T1 (sl) 2017-01-31
MEP17608A (en) 2010-06-10
SG179401A1 (en) 2012-04-27
EP2258346A2 (en) 2010-12-08
PT2258344E (pt) 2013-02-18
AU2010238573B2 (en) 2012-12-13
KR101281994B1 (ko) 2013-07-04
EA200600473A1 (ru) 2006-10-27
EP2258345B1 (en) 2016-09-21
JP2011236232A (ja) 2011-11-24
JP2016094433A (ja) 2016-05-26
NO20131743L (no) 2006-05-29
IL173939A0 (en) 2006-07-05
EP2258344A2 (en) 2010-12-08
AU2004283087A1 (en) 2005-05-06
JP2013241460A (ja) 2013-12-05
EA011924B1 (ru) 2009-06-30
DK2258346T3 (da) 2017-11-13
UA85564C2 (ru) 2009-02-10
PL2258344T3 (pl) 2013-04-30
NO334418B1 (no) 2014-03-03
HUE035985T2 (hu) 2018-06-28
HK1257502A1 (en) 2019-10-25
RS57663B1 (sr) 2018-11-30
KR101563222B1 (ko) 2015-10-26
PT2258346T (pt) 2017-10-24
MXPA06002346A (es) 2006-05-19
CY1120138T1 (el) 2018-12-12
DK2258344T3 (da) 2013-01-02
JP2007504142A (ja) 2007-03-01
SI2258346T1 (sl) 2017-12-29
ZA200801361B (en) 2011-11-30
EP2258346A3 (en) 2011-01-19
JP5395125B2 (ja) 2014-01-22
KR20110122771A (ko) 2011-11-10
NZ545499A (en) 2009-11-27
CY1113596T1 (el) 2016-06-22
KR20150044031A (ko) 2015-04-23
NO20061342L (no) 2006-05-29
RS20060140A (sr) 2008-09-29
CR20120662A (es) 2013-03-13
CN105106104A (zh) 2015-12-02
ES2666390T3 (es) 2018-05-04
SI2258344T1 (sl) 2013-03-29
EA201890737A3 (ru) 2019-01-31
EP1663183B9 (en) 2012-06-13
ATE516017T1 (de) 2011-07-15
KR20120054666A (ko) 2012-05-30
SI1663183T1 (sl) 2011-09-30
TW200522979A (en) 2005-07-16
EP2258344B1 (en) 2012-11-14
MX358033B (es) 2018-08-02
NO330282B1 (no) 2011-03-21
WO2005039551A3 (en) 2006-08-03
CA2536638A1 (en) 2005-05-06
IL254581A0 (en) 2017-11-30
PL1663183T3 (pl) 2011-10-31
CN101919858A (zh) 2010-12-22
ES2608720T3 (es) 2017-04-12
PL2942051T3 (pl) 2018-07-31
JP2018035163A (ja) 2018-03-08
ZA200601718B (en) 2009-11-25
ZA200801362B (en) 2009-03-25
CY1118505T1 (el) 2017-07-12
EP1663183B1 (en) 2011-07-13
KR20140046078A (ko) 2014-04-17
RS59969B1 (sr) 2020-03-31
HRP20110555T1 (hr) 2011-09-30
EP2258345A2 (en) 2010-12-08
CN1901884B (zh) 2012-07-25
EP2942051A1 (en) 2015-11-11
JP4815348B2 (ja) 2011-11-16
PT2942051T (pt) 2018-04-23
AU2004283087C1 (en) 2008-04-24
EA201890737A2 (ru) 2018-08-31

Similar Documents

Publication Publication Date Title
IL254581A0 (en) Solid pharmaceutical dosage form
JP2007504142A5 (ja) Ｈｉｖプロテアーゼ阻害薬固体分散物を含む固体薬物剤形
BRPI0413882A (pt) forma de dosagem farmacêutica sólida